ClinicalTrials.gg
CompletedNCT05001698Updated Aug 18, 2022

Anifrolumab PK Study for Systemic Lupus Erythematosus (SLE)

A Phase 1 interventional study of Anifrolumab in Systemic Lupus Erythematosus, sponsored by AstraZeneca. Completed at 3 sites in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2022-08-18.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing anifrolumab in Lupus Erythematosus, Systemic — 9 open to participants now, 11 under way, 6 of them phase 3. anifrolumab · Lupus Erythematosus, Systemic.

Enrollment
19th of 20
15 · median 159
Started
2021
with 3 others
Phase 1
3 of 20
1 open now
Registered
10th of 20
by date
Lead sponsor
15 of 20
AstraZeneca

Among the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic, this one is the 19th largest by enrollment, is one of 4 that started in 2021, is one of 3 in phase 1, and was the 10th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

9 of the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About anifrolumab

anifrolumab: first FDA approval 2021 (SAPHNELO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing anifrolumab in Lupus Erythematosus, Systemic, or all of them as a file.
02

Study summary

To assess the pharmacokinetic parameters of anifrolumab in Chinese participants with active systemic lupus erythematosus(SLE).

Read the detailed description

This is a Phase I, open-label, single-arm, multiple-dose study to evaluate the pharmacokinetics (PK), pharmacodynamics(PD), safety and tolerability profile of intravenously administered anifrolumab in Chinese participants with active SLE despite receiving standard of care (SOC).

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • systemic lupus erythematosus
  • SLE
  • pharmacokinetic
  • anifrolumab
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key inclusion criteria:

  1. Aged 18 to 60 years.
  2. Body weight ≥ 40 kg.
  3. Confirmed diagnosis of SLE(1997 ACR revised criteria) for ≥ 24 weeks.
  4. Must be receiving at least one of the following SOC regimens at screening:

    1. oral prednisone monotherapy: ≥ 7.5 mg/day and ≤ 40 mg/day, stable for > 2 weeks;
    2. (s) with or without OCS: antimalarials, AZA, MMF, MTX, mizoribine permitted; stable for ≥ 8 weeks; maximum dose required;
    3. Oral prednisone plus immunosuppressant: start date, stability and maximum dose required.
  5. At least one of these antibodies positive: ANA, anti-dsDNA and anti-Smith.
  6. At screening, SLEDAI-2K score ≥ 6 points.
  7. Chest imaging shows no abnormalities (unless due to SLE).
  8. No evidence or medical history of active TB, indeterminate TB should be referred to a TB specialist.
  9. All participants should use effective methods as protocol requests.

Key exclusion criteria:

  1. History or current diagnose of clinically significant non-SLE related vasculitis, severe or unstable neuropsychiatric SLE, active severe SLE-driven renal disease, catastrophic anti-phospholipid syndrome, inflammatory joint or skin disease other than SLE, non-SLE disease that has required treatment of certain dosage of .
  2. History or evidence of suicidal ideation or suicidal behavior.
  3. History or current diagnose of MTCD or overlap syndrome, unless overlap with RA or MTCD which has developed into SLE.
  4. History of recurrent infection requiring hospitalization and IV antibiotics, or opportunistic infection requiring hospitalization or IV antimicrobial treatment within 3 years of randomization, or clinically significant chronic infection within 3 months, or recent infection still under treatment.
  5. History of immunodeficient condition, positive included.
  6. Confirmed positive, or HBcAb positive and HBV DNA detectable.
  7. History of severe case of herpes zoster.
  8. Herpes zoster, CMV or EB infection which has not completely resolved within 12 weeks before screening.
  9. Acute COVID-19 infection or history of severe COVID-19.
  10. History of cancer, apart from cured squamous or basal cell carcinoma and cervical cancer in situ.
  11. Women participants with abnormal pap smear results.
  12. Prior receipt of anifrolumab ,or any commercially available biologic agent, or protein kinase inhibitor or any product within 5 half-lives, including B cell-depleting therapy, belimumab, JAK or BTK inhibitor.
  13. Known history of allergy to any component of the IP formulation or protein related products.
  14. Receipt of any of the following:

    1. Intramuscular or IV glucocorticosteroids within 6 weeks;
    2. Any live or attenuated vaccine within 8 weeks;
    3. Any restricted medication listed in protocol;
    4. Blood transfusion within 4 weeks.
  15. Certain laboratory test results requirements.
  16. Concurrent enrolment in another clinical study.
  17. History or current alcohol, drug or chemical abuse within 1 year.
  18. Major surgery within 8 weeks or planned elective major surgery.
  19. Blood donation or blood loss more than 400 mL within 3 months.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Anifrolumab

    All eligible participants will receive anifrolumab via intravenous (IV) infusion pump.

    Biological: Anifrolumab

Interventions

06

What researchers measure

Primary outcomes

  1. Time to maximum observed plasma concentration (Tmax) of anifrolumab.

    To characterise the pharmacokinetic (PK) profile of anifrolumab via intravenous (IV) infusion.

    Time frame: Day 1 to Day 141

  2. Maximum observed plasma concentration (Cmax) of anifrolumab.

    To characterise the pharmacokinetic (PK) profile of anifrolumab via intravenous (IV) infusion.

    Time frame: Day 1 to Day 141

  3. Area under plasma concentration-time curve over dosing interval (AUC[tau]) of anifrolumab.

    To characterise the pharmacokinetic (PK) profile of anifrolumab via intravenous (IV) infusion.

    Time frame: Day 1 to Day 141

  4. Pre-dose trough concentration (Ctrough) of anifrolumab.

    To characterise the pharmacokinetic (PK) profile of anifrolumab via intravenous (IV) infusion.

    Time frame: Day 1 to Day 141

  5. The volume of plasma cleared of drug per unit time (CL) of anifrolumab.

    To characterise the pharmacokinetic (PK) profile of anifrolumab via intravenous (IV) infusion.

    Time frame: Day 1 to Day 141

Secondary outcomes

  1. Incidence of adverse events

    To characterise the safety and tolerability of anifrolumab via IV infusion.

    Time frame: From Screening, Day 1 to Day 141

  2. Incidence of abnormal vital signs

    To characterise the safety and tolerability of anifrolumab via IV infusion.

    Time frame: From Screening, Day 1 to Day 141

  3. Incidence of abnormal laboratory parameters

    To characterise the safety and tolerability of anifrolumab via IV infusion.

    Time frame: Day 29, 57, 85, 113, 141

  4. Anti-drug antibodies (ADA)

    To characterise the immunogenicity of anifrolumab via IV infusion.

    Time frame: Day 1, 85, 113, 141

  5. 21-gene Type I interferon PD signature

    To evaluate the IFN level change from baseline after administration of anifrolumab.

    Time frame: Screening, Day 29, 85, 113, 141

07

Study locations

3 sites
  • Research Site
    Nantong, 226001, China
  • Research Site
    Shanghai, 200025, China
  • Research Site
    Shanghai, 200040, China
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Jun 2022, 10 months.

Of 108 industry-sponsored phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's 10 months is below that.

Counting every sponsor, half of 147 studies reached it within 28 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2021
First posted
Aug 12, 2021
StartActual
Jul 27, 2021
Primary completionActual
Jun 2, 2022
CompletionActual
Jun 2, 2022
Last update
Aug 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05001698
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 12, 2021
Start date
Jul 27, 2021
Primary completion
Jun 2, 2022
Completion
Jun 2, 2022
Last update
Aug 18, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anifrolumab

Start the discussion